Rating Change: Is It Finally Time? Maxim Group Starts Coverage On SciClone Pharmaceuticals (NASDAQ:SCLN) with $14.00 Price Target

November 29, 2016 - By Darrin Black

Rating Change: Is It Finally Time? Maxim Group Starts Coverage On SciClone Pharmaceuticals (NASDAQ:SCLN) with $14.00 Price Target

Why Maxim Group Gives SciClone Pharmaceuticals (NASDAQ:SCLN) $14.00 Price Target

Investment analysts at Maxim Group started coverage on shares of SciClone Pharmaceuticals (NASDAQ:SCLN) in a a report sent to investors and clients on Tuesday morning. The broker set a Buy rating on the stock. Maxim Group’s price target of $14.00 suggests potential of 37.93% from the stock’s last stock close price.

The stock decreased 0.98% or $0.1 during the last trading session, hitting $10.15. About 662,426 shares traded hands or 74.23% up from the average. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has declined 22.11% since April 26, 2016 and is downtrending. It has underperformed by 27.37% the S&P500.

Analysts await SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) to report earnings on March, 9.

Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.16, from 1.18 in 2016Q1. The ratio improved, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.

New York State Common Retirement Fund reported 63,619 shares or 0% of all its holdings. Moreover, Stevens Cap Management L P has 0.01% invested in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 11,944 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 4,238 shares. Deere & last reported 20,413 shares in the company. Sensato Limited last reported 2.35% of its portfolio in the stock. Springbok Management Ltd Liability, a New York-based fund reported 5,600 shares. Blackrock last reported 0% of its portfolio in the stock. Blackrock Advsr Limited Liability Company owns 378,006 shares or 0.01% of their US portfolio. The Florida-based State Board Of Administration Of Florida Retirement has invested 0.01% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Moreover, Hanseatic Mgmt Svcs has 0% invested in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 62 shares. The United Kingdom-based Legal And General Public Limited Com has invested 0% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Fincl Bank Of Ny Mellon Corp, a New York-based fund reported 597,540 shares. Balyasny Asset Management Ltd holds 0% or 11,175 shares in its portfolio. Mufg Americas Hldgs has invested 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Principal Fin accumulated 0.01% or 351,202 shares.

Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 14 selling transactions for $11.13 million net activity. Cheung Wilson Wai-Shun had sold 1,872 shares worth $19,370 on Monday, August 29. King Robert also sold $506,623 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Friday, August 12. $371,892 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) was sold by Blobel Friedhelm. 40,500 shares were sold by Zhao Hong, worth $421,605 on Friday, August 12. 120,000 shares were sold by Hawkins Richard J, worth $1.24 million. CHANG NANCY T also sold $257,896 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) shares. Shares for $323,574 were sold by Meng Chuncai.

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $520.73 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.56 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.

According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”

SCLN Company Profile

SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

More recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on October 28, 2009. Also Prnewswire.com published the news titled: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On …” on October 25, 2016. Quotes.Wsj.com‘s news article titled: “DOW JONES, A NEWS CORP COMPANY” with publication date: February 12, 2011 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>